UFT® modulated with leucovorin in advanced colorectal cancer: Oncopaz experience

Oncology (Switzerland)

Volumn 54, Issue , 1997, Pages 24-29

  BarÓn, Manuel Gonzàlez ^a   Feliu, Jaime ^a   GirÓn, C Garcia ^b   Espinosa, J ^c   Martinez, B ^d   Blanco, E ^e   Crespo, M C ^f   OrdOnez A ^a   Espinosa, E ^a   de Castro, J ^a   Juarez F ^g   Colmenarejo, A ^h  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^c HOSPITAL RUBER INTERNACIONAL   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL INFANTA CRISTINA   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^h Hospital del Aire   (Spain)

Author keywords

Colorectal cancer; Fluoropyrimidines; Leucovorin; UFT

Indexed keywords

FOLINIC ACID; TEGAFUR; UFT; URACIL; ANTINEOPLASTIC AGENT; UFT(R) DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMACH PAIN; VOMITING; ARTICLE; COLORECTAL TUMOR; DRUG COMBINATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; HUMANS; LEUCOVORIN; TEGAFUR; URACIL;

EID: 0030639034     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227742     Document Type: Article

References (28)

1. Piedbois P, Buyse M, Rustum YM, Machover D, Erlichman C, Carlson RW, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response. J Clin Oncol 1992;6:896-903.
2. Evans RM, Laskin JD, Hakala MT: Effect of excess folates and desoxyinosine on activity and site of action 5-fluorouracil. Cancer Res 1981;41:3288-3295.
3. Trave F, Rustum YM, Petrelli N, Herrera L, Mittelman A, Frank C, et al: Plasma and tumor tissue pharmacology of high dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol 1988;6:1184-1191.
4. Keyomarsi K, Moran RG: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986;46:5229-5235.
5. Hines JD, Zakcm MH, Adelstein DJ, Giroski P, Blum MR, Rustum YM: Bioavailability of high-dosc oral leucovorin. Monogr Natl Cancer Inst 1987;5:57-60.
6. Yin MB, Zakzrewski SF, Hakala MT: Relationship of cellular folate cofactor pools to the activity of fluorouracil. Mol Pharmacol 1983; 32:190-197.
7. Allegra CJ: Biochemical modulation: A modality that has come of therapeutic age. J Clin Oncol 1991;9:1723-1726.
8. Straw J, Szapary D, Wynn WT: Pharmacokinetics of the diasteroisomcrs of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 1984:44:3114-3119.
9. MacMillan WE, Wolberg WH, Welling PG: Pharmacokinetics of 5-fluorouracil in humans. Cancer Res 1978;38:3479-3482.
10. Drewinko B, Lang LY: Cellular basis for the inefficiency of 5-fluorouracil in human colon carcinoma. Cancer Treat Rep 1985;69:1391-1398.
11. Peters GJ, van del Wilt CL, van Groeningen CJ, Smid K, Mieijer S, Pinedo HM: Thymidy-late synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J Clin Oncol 1994; 12:2035-2042.
12. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, et al: Association of intratumoral pharmacokinetics with clinical response. Lancet 1994;343:1184-1187.
13. Peters GJ, van der Wilt CL, van Grocningen CJ: Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur J Cancer 1994;30:1411-1413.
14. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassanville O, Renee N, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-1670.
15. Toide H, Aklyoshi H, Minato Y, Okuda M, Fujii S: Comparative studies on metabolism of 2-(tc:Rahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 1977:68:553-560.
16. Fujii S, Irenaka K, Fakushima M, Shirasaka T: Effect of Uracil and its derivates on the antitumor activity of clinical doses of (2-tetrahydro-furyl)-5-fluorouracil. Gann 1978:69:763-772.
17. Fujii S, Kitano S, Irenaka K, Shirasaka T: Effect of coadministration of Uracil or cytosine on the antitumor activity of clinical doses of (2-tctrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Jpn J Cancer Res 1979; 70:209-214.
18. Taguchi T, Nakano Y, Fujii S, Shirasaka T: Determination of 5-fluorouracil levels in tumors, blood and other tissues. Cancer Chemother 1978;5:1167-1172.
19. Murakami M, Ohta K: Clinical results of UFT' therapy for malignant tumors under cooperative study. Cancer Chemother 1980:9: 1911-1916.
20. Estape J, Diaz Rubio E, Guillem V, Montero JM, Garcia-Condc J, Martin M, et al: Ensayo en fase II del UFT* en div ersos tumorcs sdli-dos. Neoplasia 1986;3:57-60.
21. Gonzalez Baron M, Feliu JJ, Ordonez A, Colmenarejo A, Espinosa E, Zamora P, et al: Phase I study of UFT* plus leucovorin in advanced colorectal cancer: A double modulation proposal. Anticancer Res 1993;13:759-762.
22. Gonzalez Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez B, et al: Efficacy of oral Tegafur modulation by Uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 1995;31:2215-2219.
23. Saltz L, Young C, Currie V, Tong W, Conti J, Esposito A, et al: Phase I and clinical pharmacologic studies of oral UFT* alone and with oral leucovorin (LV) (abstract). Proc Am Soc Clin Oncol 1993;12:149.
24. Jaiyesini I, Pazdur R, Ho DH, Lassere Y, Moore D Jr., Bready B, et al: Phase I trial UFT® (ftorafur plus Uracil) and lcucovorin:28 day schedule (abstract). Proc Am Soc Clin Oncol 1993; 12:152.
25. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Path YZ, et al: Phase II trial of uracil and Tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994:12: 2296-2300.
26. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, et al: A fixed-ratio combination of Uracil and ftorafur (UFT*) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782-785.
27. Erlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469-475.
28. Buroker TR, sO’Connell MJ, Wieand HS, Krook JE. Gcrstner JB, Mailliard JA, et al: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12:14-20.